The health system value committee moats: P&T, VAC, and the P&L that never adds up.

The medical-pharmacy benefit divide in managed care is an externally imposed architecture. Separate vendors, contracts, claims routing, and regulatory classification created two decision authorities for the same patient's care. Health systems did not inherit that problem. They constructed an equivalent one from scratch, from inside the organization, and have largely left it running untouched.

The P&T committee and the value analysis committee are not identical to the payer moat, but they produce the same outcome. Two separate bodies evaluate different dimensions of the same clinical and economic decision, with limited shared vocabulary, no formal reconciliation mechanism, and separate P&Ls that each measure success independently of the other. In the payer context the architecture at least has external origins. In the health system, the moat is self-built.

The moat has a different foundation

In managed care the divide is structurally enforced. The PBM holds data the health plan does not. Claims routing separates the adjudication. Contractual relationships create distinct accountability chains. The moat is load-bearing in the business model. In the health system, P&T and the value analysis committee sit inside the same organization and frequently report to the same chief nursing or chief medical officer. No separate vendor makes the divide structurally necessary. The moat is cognitive and cultural.

That distinction matters because cognitive and cultural moats are, in theory, easier to dismantle. No contract has to be renegotiated and no vendor relationship has to be unwound. In practice they are often more durable than structural ones, because no one owns the gap explicitly and the incentive to close it is diffuse. Structural moats have a visible forcing function. Cultural moats persist because the organization has adapted to them, and adaptation gets mistaken for function.

P&T was designed to evaluate clinical evidence and control formulary cost. That is a legitimate and necessary function. It was not designed to aggregate clinical experience from the floor, to formally weight the voice of prescribers, advanced practice providers, and nurses in therapeutic decisions, or to account for downstream operational costs that never appear in the pharmacy P&L. The committee does what it was designed to do. The design is the limitation. The value analysis committee has the same structural problem in the opposite direction. Supply chain and finance drive the agenda, and clinical voice is invited in for legitimization, usually after the cost analysis is complete. Neither committee is wrong. Both are incomplete by design.

Who sits at each table, and what they optimize

Before the failure mode makes sense, it helps to be precise about what these two committees are, because they are not interchangeable and most people outside the building have never seen either one work.

The pharmacy and therapeutics committee governs the formulary. Its membership weights toward pharmacy leadership and prescribing physicians, usually with clinical specialists, an antimicrobial steward, nursing representation, and quality and safety input, supported by drug information pharmacists who prepare the evidence monographs. Its scope is to evaluate clinical evidence, safety, and cost, and to set formulary inclusion, therapeutic tier, restrictions, therapeutic interchange, and medication use policy. The people who live inside those decisions every day, the frontline prescribers, advanced practice providers, and nurses, are rarely formal voting members.

The value analysis committee governs devices, supplies, and technology. It convenes supply chain and finance alongside nursing, physician and service-line leaders, quality, and operations, and it evaluates products through a procurement and operational-fit lens. The useful way to see it is to ask what moves each stakeholder, because the same product reads differently depending on which chair you occupy.

High and low reflect each role's typical level of interest across the three lenses. Stakeholder lenses adapted from frameworks by Ajay Singh, Quality Reviews (q-reviews.com), and Kevin Mehta, 3 Pillars Solutions.

No single row is wrong, and that is the point. Six stakeholders bring six defensible priorities, and the same split appears at the executive level, where surveyed C-suite leaders sort their goals into operational cost savings, strategic growth and revenue, and workforce. The lens a decision meets depends on who is in the room when it is made, and neither the value analysis committee nor P&T is built to reconcile all of them against a single number.

The P&L problem

The relationship between clotting factor management and transfusion medicine is one of the clearest illustrations of how committee-level optimization produces system-level loss.

Start with the ledgers themselves, because the problem lives in how they are drawn. A health system does not run one P&L. The pharmacy department carries drug acquisition cost. Surgical services carries operating room time. The blood bank carries transfusion products. Critical care carries the ICU bed, the ventilator, and the length of stay. Each is a separate cost center with its own budget owner and its own definition of a good year. A formulary restriction is decided inside one of those ledgers, and its consequences land in the others.

Clotting factor concentrates are used in patients with hemophilia and von Willebrand disease, and increasingly in surgical patients who require focused hemostasis after major surgery such as cardiac or orthopedic procedures, or for anticoagulation reversal before or during a procedure. They are among the most expensive pharmaceutical products by unit cost. When P&T applies a formulary restriction to them, the decision is typically made on acquisition cost per unit. That is a defensible metric within the pharmacy P&L and an incomplete one for the health system.

What the restriction analysis routinely omits is the downstream surgical consequence of inadequate hemostasis, and the omission is not small. A patient who does not receive timely or appropriate factor replacement bleeds longer in the operating room, and prolonged OR time is expensive in ways that reach well beyond the blood bank. Bleeding that a more aggressive factor strategy would have controlled often escalates to a full hemostatic transfusion, potentially multiple units of packed red cells, fresh frozen plasma, and cryoprecipitate, each a blood bank cost rather than a pharmacy cost. The consequence upstream is rarely a possibility and closer to a certainty. It is not a probable ICU admission but a definitive one, frequently with prolonged ICU length of stay and extended time on the ventilator. None of those costs appear on the formulary committee's ledger. The pharmacy P&L looks disciplined while surgical services, the blood bank, and critical care absorb the consequence.

The governance mechanism makes the blind spot self-reinforcing. Factor restriction criteria in P&T policy tend to be written in black and white, and when utilization runs above expectation the hospital deploys a retrospective medication use evaluation to understand it. That review examines the drug against the policy, and it can tighten the criteria further, all without a total cost lens. The instrument built to police utilization has no line of sight to the operating room, the blood bank, or the critical care cost it may be creating.

The pattern repeats across disease states, and two further cases sharpen it. One is a formulary-preferred pediatric antiarrhythmic whose monitored initiation runs longer and less predictably than the agent it displaced. The other is an expensive intravenous Class III antiarrhythmic that can compress a multi-day monitored oral-loading admission into a fraction of the time. What P&T optimizes in each, and what the rest of the system absorbs or gives up, runs in opposite directions.

None of these examples is hypothetical. All three are categories where the committee running the cost analysis sees one slice of total cost and stays blind to the rest, sometimes hiding a downstream cost the restriction created and sometimes hiding the capacity and margin it gave away. This is the structural error. The committees are not the problem in isolation. The P&L fragmentation is what makes them dangerous. Removing the committee barrier without consolidating financial accountability does not solve the problem. It moves the argument to a different venue and leaves the incentives unchanged. Health system CFOs who are serious about total cost of care have to confront this directly, because the committee structure is a derivative of the budget structure, and integrated decision-making cannot emerge from a governance architecture built on fragmented accountability.

The gatekeeper identity

Pharmacy's role in this dynamic deserves examination without diplomatic cover, because the profession has largely built its own adversarial reputation and does not examine it honestly enough. Formulary restriction, prior authorization management, therapeutic substitution, and cost containment are legitimate tools that got elevated into a professional worldview. The implicit message to every other clinical stakeholder became that pharmacy evaluates and approves, and its criteria are the criteria that count. That is not partnership. It is toll collection with clinical credentials.

Physician resistance to pharmacy decisions is not primarily about clinical disagreement. It is about process. Prescribers, advanced practice providers, and nurses who work with a drug every day, who manage the patient who did not respond to the formulary alternative, who see the access gap the committee never modeled, were never formally part of the decision. Occasionally their experience surfaces in a drug monograph comment section. Mostly it does not surface at all.

The profession has done significant work in clinical pharmacy practice, in embedding pharmacists in care teams, and in demonstrating patient-level value. That work is real. At the P&T level, the governance model has not caught up. The committee was designed to manage cost and evaluate evidence, and the voice of the clinical customer, meaning not just patients but the physicians, advanced practice providers, and nurses who use the formulary as a daily operating constraint, was never part of the architecture. The result is a committee that is often right on the clinical merits and chronically wrong on the organizational dynamics. The restriction may be defensible. The process by which it was reached, and the way it is communicated and enforced, generates an adversarial dynamic that persists long after any individual decision is forgotten. Health systems where pharmacy leadership has deliberately repositioned from formulary steward to partner in care delivery show a different pattern. The decisions are not necessarily more permissive. The buy-in is categorically different. That repositioning requires a different kind of pharmacist in the role and a different mandate from the executive team, and it is not the norm.

The data is not the gap

Health systems have more data than at any point in their history. Cost accounting systems, EHR analytics, supply chain platforms, claims feeds, and pharmacy dispensing data tied to patient-level outcomes are now available in almost every system operating at scale. The information required to understand the full cost of a formulary restriction across both the pharmacy and clinical P&Ls exists. The factor product utilization pattern is not invisible. The relationship between restriction decisions and downstream outcomes is not unmeasurable. The problem is that no one has assembled the synthesis that crosses the committee boundary in a format that creates shared accountability for the result.

Name the gap precisely, because vagueness is what lets it persist. The gap is not data. It is collated clinical and financial information, made actionable across every P&L the decision touches, with the cost consequences and the trade-offs stated explicitly rather than left implied. Raw utilization, acquisition cost, transfusion volume, and length of stay all exist in separate systems today. The missing artifact is the reconciled view that puts them in one place, attaches the decision to its full consequence, and makes the trade-off a choice someone actually owns.

The missing intelligence is not another dataset. It is the consolidated business case that neither committee is currently required to produce, reviewed by someone with both the authority and the incentive to act on it. That business case forces a different question. Not whether the drug is cost-effective for pharmacy, and not whether the device meets value analysis thresholds, but what the total cost of the decision is across every P&L it touches. That question has a clear owner in very few health systems. Most organizations have a pharmacy director answerable to the pharmacy P&L, a supply chain leader answerable to acquisition cost, a chief medical officer with clinical quality responsibility, and a CFO somewhere above all of them who in theory owns the consolidated view. In practice the CFO rarely has the clinical depth to challenge a formulary decision, and the clinical leaders rarely have the economic accountability to demand the consolidated number. The gap between them is where the most expensive decisions in the health system get made by default.

The structural intervention

Unified committees are a common proposal and a limited solution. Merging P&T and the value analysis committee into a single body changes the meeting room but not the incentive structure. The pharmacy budget center and the clinical operations budget center still exist as separate entities. The people in the room still report into different P&Ls. The consolidated number still does not get calculated unless someone is explicitly accountable for it.

The more durable intervention is a designated analytical function, not a new committee, that runs total cost analyses on decisions crossing committee boundaries before those decisions are finalized. This is not a new platform. It is a defined responsibility, assigned to a person or a team, with explicit authority to surface the consolidated business case to executive leadership when the committee-level analysis is incomplete. The person in that role needs enough clinical credibility to engage P&T on formulary evidence and enough financial fluency to construct a total cost model the CFO will take seriously. That profile describes a pharmacist with health economics training, a clinical pharmacoeconomist, or in some organizations a chief pharmacy officer operating at true C-suite scope. The title matters less than the mandate. Health systems that get this right are not necessarily the ones with the most sophisticated analytics infrastructure. They are the ones where the executive team has explicitly named the governance gap and assigned someone to close it. That is a leadership decision, not a technology decision.

The read

The payer world built its medical-pharmacy divide through external architecture. Health systems built theirs from inside the organization, through committee design, budget center structure, and a professional identity that chose restriction over partnership as its organizing principle.

That is the gray space. The consolidated business case for decisions that cross committee boundaries is not being produced, and the voice of the clinical customer is not formally weighted in the governance that shapes daily practice. The white space is that the data to close both gaps already exists, which means the first system in a market to assign a real owner to the consolidated number captures total cost of care its competitors are still spending against blind. It requires naming a problem currently diffuse enough that everyone can plausibly claim it belongs to someone else. That is a solvable problem. It is also a choice.

Frequently asked questions

What are the P&T and value analysis committees in a health system?

The pharmacy and therapeutics committee evaluates clinical evidence and controls formulary cost. The value analysis committee evaluates devices, supplies, and technology through a procurement and operations lens. They are two separate governance bodies assessing different dimensions of the same clinical and economic decisions, usually with limited shared vocabulary and no formal reconciliation mechanism.

How is the health system committee moat different from the payer medical-pharmacy divide?

In managed care the divide is externally imposed and structurally enforced through separate vendors, contracts, and claims routing, which makes it load-bearing in the business model. In the health system, P&T and the value analysis committee usually sit inside the same organization and often report to the same executive. The moat is cognitive and cultural rather than structural, which should make it easier to dismantle and in practice often makes it more durable, because no one owns the gap explicitly.

Why does separating P&T and the value analysis committee raise total cost of care?

Each committee has structural visibility into one slice of cost and structural blindness to the rest. A formulary restriction decided on drug acquisition cost can drive longer operating room time, blood bank utilization, and ICU admissions that never appear on the pharmacy ledger. The pharmacy P&L records a saving while other service lines absorb a larger consequence, and because no one calculates the consolidated number, the net loss is invisible.

Is merging P&T and the value analysis committee the solution?

Merging the committees changes the meeting room but not the incentive structure. The separate budget centers still exist and the people in the room still report into different P&Ls, so the consolidated number still does not get calculated unless someone is explicitly accountable for it. The more durable intervention is a designated analytical function that runs total cost analyses on decisions crossing committee boundaries before those decisions are finalized.

Why do clinicians resist pharmacy formulary decisions?

Physician resistance is usually about process rather than clinical disagreement. Prescribers, advanced practice providers, and nurses who manage the patient who did not respond to the formulary alternative were never formally part of the decision. Formulary restriction and prior authorization are legitimate tools that hardened into a professional worldview, and the committee is often right on the clinical merits and chronically wrong on the organizational dynamics of how the decision was reached and enforced.

Who should own the consolidated total cost analysis?

The role needs enough clinical credibility to engage P&T on formulary evidence and enough financial fluency to build a total cost model a CFO will take seriously. That profile fits a pharmacist with health economics training, a clinical pharmacoeconomist, or a chief pharmacy officer operating at true C-suite scope. The title matters less than the mandate, and assigning it is a leadership decision rather than a technology decision.

Method and note

This analysis reflects the author's professional experience across health system clinical transformation, pharmacy strategy, and health economics. The clotting factor and pediatric antiarrhythmic examples are illustrative composites of well-documented clinical and operational dynamics rather than accounts of any single institution or event, and the specific cost pathways they describe will vary by organization, payer mix, and case.

This piece is analysis and commentary based on professional experience and general industry structures as of the date noted, and nothing in it constitutes legal, clinical, or financial advice. Descriptions of committee governance, formulary practice, and cost accounting are general characterizations and are not directed at any specific institution. Interpretive conclusions are the author's opinion, offered for analytical discussion. All views reflect independent professional judgment and do not represent the views or positions of any current or former employer or affiliated organization.